Atara Biotherapeutics Inc ATRA:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
14.60 0.10   0.69%--369,217197.3K
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. Chart as of 04:00 PM ET 12/12/2017

Latest News Headlines for Atara Biotherapeutics Inc

No News for Atara Biotherapeutics Inc

Peers Information HelpATRA Atara Biotherapeutics Inc vs. Peers

No Peers data currently available for ATRA

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

http://www.atarabio.com/

Loading...

expand, down-facing arrow indicating expanded view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open14.55
Previous Close14.50
Day High14.775
Day Low14.40
52 Week High3/13/2017 | 23.00
52 Week Low6/15/2017 | 11.80
% Off 52 Week High-36.52%
% Off 52 Week Low23.73%
Beta (5 Yr)--
Volatility Avg12/11/2017 | 64.03
10-Day Avg. Volume197,320
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)9/30/2017 | -3.47
P/E Ratio9/30/2017 | --
Market CapSmall Cap | 446.70M
Shares Outstanding30.60M
Float27.2M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short5.06M
Short Ratio44.9
Short % of Float18.63%
As of 11/30/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.